Pansiptin Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Sitagliptin

Indications/Uses

Adjunct to diet & exercise to improve glycemic control in patients w/ type 2 DM. In combination w/ metformin, sulfonylurea, metformin & sulfonylurea (as dual therapy), PPARγ agonist (eg, thiazolidinediones) & insulin for type 2 DM as initial therapy or when the single agent alone, w/ diet & exercise, does not provide adequate glycemic control.

Dosage/Direction for Use

Recommended dose: 100 mg once daily. Moderate renal impairment (eGFR ≥30 mL/min/1.73 m² to <45 mL/min/1.73 m²) 50 mg once daily. Severe renal impairment (eGFR ≥15 mL/min/1.73 m² to <30 mL/min/1.73 m²) or ESRD (eGFR <15 mL/min/1.73 m²) including those requiring hemodialysis or peritoneal dialysis 25 mg once daily. May be administered w/o regard to dialysis timing.

Administration

May be taken with or without food.

Contraindications

History of serious hypersensitivity to sitagliptin (eg, anaphylaxis or angioedema).

MIMS Class

Antidiabetic Agents

ATC Classification

A10BH01 - sitagliptin ; Belongs to the class of dipeptidyl peptidase 4 (DPP-4) inhibitors. Used in the treatment of diabetes.

Regulatory Classification

POM

Presentation/Packing

Form

Pansiptin film-coated tab 100 mg

Packing/Price

1's

Form

Pansiptin film-coated tab 25 mg

Packing/Price

1's

Form

Pansiptin film-coated tab 50 mg

Packing/Price

1's

Pansiptin

sitagliptin

Manufacturer:

SAG Manufacturing S.L.U.